» Articles » PMID: 14871829

Energy Substrate Modulates Mitochondrial Structure and Oxidative Capacity in Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2004 Feb 12
PMID 14871829
Citations 351
Authors
Affiliations
Soon will be listed here.
Abstract

Comparative analysis of cytoplasmic organelles in a variety of tumors relative to normal tissues generally reveals a strong diminution in mitochondrial content and in oxidative phosphorylation capacity. However, little is known about what triggers these modifications and whether or not they are physiologically reversible. We hypothesized that energy substrate availability could play an important role in this phenomenon. The physiological effects of a change in substrate availability were examined on a human cancer cell line (HeLa), focusing specifically on its ability to use glycolysis versus oxidative phosphorylation, and the effect that energy substrate type has on mitochondrial composition, structure, and function. Changes in oxidative phosphorylation were measured in vivo by a variety of techniques, including the use of two novel ratiometric green fluorescent protein biosensors, the expression level of oxidative phosphorylation and some glycolytic enzymes were determined by Western blot, mitochondrial DNA content was measured by real-time PCR, and mitochondrial morphology was monitored by both confocal and electron microscopy. Our data show that the defective mitochondrial system described in cancer cells can be dramatically improved by solely changing substrate availability and that HeLa cells can adapt their mitochondrial network structurally and functionally to derive energy by glutaminolysis only. This could also provide an explanation for the enhancement of oxidative phosphorylation capacity observed after tumor regression or removal. Our work demonstrates that the pleomorphic, highly dynamic structure of the mitochondrion can be remodeled to accommodate a change in oxidative phosphorylation activity. We compared our finding on HeLa cells with those for nontransformed fibroblasts to help distinguish the regulatory pathways.

Citing Articles

The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets.

Takasu M, Kishi S, Nagasu H, Kidokoro K, Brooks C, Kashihara N Kidney Int Rep. 2025; 10(2):328-342.

PMID: 39990900 PMC: 11843125. DOI: 10.1016/j.ekir.2024.10.035.


An AMP-activated protein kinase-PGC-1α axis mediates metabolic plasticity in glioblastoma.

Sauer B, Kueckelhaus J, Lorenz N, Bozkurt S, Schulte D, Weinem J Clin Transl Med. 2024; 14(11):e70030.

PMID: 39552019 PMC: 11570551. DOI: 10.1002/ctm2.70030.


Mitochondrial destabilization in tendinopathy and potential therapeutic strategies.

Cheng L, Zheng Q, Qiu K, Ker D, Chen X, Yin Z J Orthop Translat. 2024; 49:49-61.

PMID: 39430132 PMC: 11488423. DOI: 10.1016/j.jot.2024.09.003.


Mitochondrial bioenergetics stimulates autophagy for pathological MAPT/Tau clearance in tauopathy neurons.

Jia N, Ganesan D, Guan H, Jeong Y, Han S, Rajapaksha G Autophagy. 2024; 21(1):54-79.

PMID: 39171695 PMC: 11702964. DOI: 10.1080/15548627.2024.2392408.


Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.

Enzenmuller S, Niedermayer A, Seyfried F, Muench V, Tews D, Rupp U Cell Death Dis. 2024; 15(7):475.

PMID: 38961053 PMC: 11222427. DOI: 10.1038/s41419-024-06864-7.